Related Experiment Video
Updated: Mar 9, 2026
A Chromatin Assay for Human Brain Tissue
Published on: March 21, 2008
Analysis of differential gene expression mediated by clozapine in human postmortem brains
Brian J Lee1, Luigi Marchionni2, Carrie E Andrews3
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA; Cellular and Molecular Medicine Program, Johns Hopkins University School of Medicine, 1830 E. Monument St., Baltimore, MD 21205, USA.
Abstract:
Clozapine is the only medication indicated for treating refractory schizophrenia, due to its superior efficacy among all antipsychotic agents, but its mechanism of action is poorly understood. To date, no studies of human postmortem brain have characterized the gene expression response to clozapine. Therefore, we addressed this question by analyzing expression data extracted from published microarray studies involving brains of patients on antipsychotic therapy. We first performed a systematic review and identified four microarray studies of postmortem brains from antipsychotic-treated patients, then extracted the expression data. We then performed generalized linear model analysis on each study separately, and identified the genes differentially expressed in response to clozapine compared to other atypical antipsychotic medications, as well as their associated canonical pathways. We also found a number of genes common to all four studies that we analyzed: GCLM, ZNF652, and GYPC. In addition, pathway analysis highlighted the following processes in all four studies: clathrin-mediated endocytosis, SAPK/JNK signaling, 3-phosphoinositide synthesis, and paxillin signaling. Our analysis yielded the first comprehensive compendium of genes and pathways differentially expressed upon clozapine treatment in the human brain, which may provide insight into the mechanism and unique efficacy of clozapine, as well as the pathophysiology of schizophrenia.
Insights
This study reveals key genes and pathways affected by clozapine in the human brain, offering new insights into treating refractory schizophrenia. Understanding clozapine
Area of Science:
- Neuroscience
- Genomics
- Pharmacology
Background:
- Clozapine is the sole effective treatment for refractory schizophrenia.
- Its precise mechanism of action remains largely unknown.
- No prior studies have analyzed clozapine's gene expression effects in human postmortem brains.
Purpose of the Study:
- To characterize the gene expression response to clozapine in the human brain.
- To identify genes and pathways uniquely altered by clozapine compared to other antipsychotics.
- To provide insights into clozapine's efficacy and schizophrenia pathophysiology.
Main Methods:
- Systematic review of four microarray studies on postmortem brains from patients on antipsychotic therapy.
- Extraction and analysis of gene expression data using generalized linear models.
- Identification of differentially expressed genes and associated canonical pathways.
Main Results:
- Identified GCLM, ZNF652, and GYPC as common genes across all studies.
- Pathway analysis revealed significant involvement of clathrin-mediated endocytosis, SAPK/JNK signaling, 3-phosphoinositide synthesis, and paxillin signaling.
- Generated a comprehensive compendium of clozapine-responsive genes and pathways.
Conclusions:
- This research provides the first human postmortem brain gene expression profile for clozapine.
- The findings may elucidate clozapine's unique efficacy in refractory schizophrenia.
- The identified genes and pathways offer potential targets for understanding schizophrenia and developing novel treatments.
